Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: Observational cohort study

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Chiu, Christine L ^a   Lujic, Sanja ^a   Thornton, Charlene ^a   O'Loughlin, Aiden ^a   Makris, Angela ^a,b   Hennessy, Annemarie ^a   Lind, Joanne M ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; AGING; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSAL HORMONE THERAPY; OBSERVATIONAL STUDY; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; UTERUS;

AGE DISTRIBUTION; AGED; COHORT STUDIES; DEMOGRAPHY; FEMALE; HEALTH; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTENSION; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; RISK FACTORS;

EID: 84863856940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040260     Document Type: Article

References (24)

1. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, et al. (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933-941.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA: the journal of the American Medical Association 288: 321-333.
3. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465-1477.
4. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S, (2007) Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 55: 1056-1065.
5. Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, et al. (2000) Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 36: 780-789.
6. Trial TWGftP, (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273: 199-208.
7. van Ittersum FJ, van Baal WM, Kenemans P, Mijatovic V, Donker AJ, et al. (1998) Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 11: 1147-1152.
8. Kaya C, Dincer Cengiz S, Cengiz B, Akgun G, (2006) The long-term effects of low-dose 17beta-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study. Climacteric 9: 437-445.
9. Karalis I, Beevers G, Beevers M, Lip G, (2005) Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood Press 14: 38-44.
10. Ford ES, Cooper RS, (1991) Risk factors for hypertension in a national cohort study. Hypertension 18: 598-606.
11. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P, (1996) Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 143: 971-978.
12. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA: the journal of the American Medical Association 291: 1701-1712.
13. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, et al. (2009) Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2: 228-239.
14. Freeman EW, Sherif K, (2007) Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 10: 197-214.
15. Tuomikoski P, Haapalahti P, Sarna S, Ylikorkala O, Mikkola TS, (2010) Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. Annals of medicine 42: 334-343.
16. Bechlioulis A, Kalantaridou SN, Naka KK, Chatzikyriakidou A, Calis KA, et al. (2010) Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J Clin Endocrinol Metab 95: 1199-1206.
17. Sassarini J, Fox H, Ferrell W, Sattar N, Lumsden MA, (2011) Vascular function and cardiovascular risk factors in women with severe flushing. Clinical endocrinology 74: 97-103.
18. Food and Drug Administration DoHaHS (2009) Consumer information by audience: For women: Menopause and Hormones.
19. Banks E, Redman S, Jorm L, Armstrong B, Bauman A, et al. (2008) Cohort profile: the 45 and up study. Int J Epidemiol 37: 941-947.
20. Mealing NM, Banks E, Jorm LR, Steel DG, Clements MS, et al. (2010) Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs. BMC Med Res Methodol 10: 26.
21. Bauman A, Ford I, Amstrong T, (2001) Trends in Population Levels of Reported Physical Activity in Australia 1997, 1999 and 2000. Canberra: Australian Sports Commission.
22. Australian Institute of Health and Welfare (2003) The active Australia survey: A guide and manual for implemenation analysis and reporting. Canberra: Australian Institute of Health and Welfare.
23. Rothman KJ, (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43-46.
24. Perneger TV, (1999) Adjusting for multiple testing in studies is less important than other concerns. BMJ 318: 1288.